/
AMPH
$20.71-$1.07 (-4.91%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$960.3M
44M shares
52-week range
$16.65 – $31.26
28% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.55
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $294.7M | $322.4M | $349.8M | $437.8M | $499.0M | $644.4M | $732.0M | $719.9M |
| Cost of revenue | $187.7M | $190.4M | $206.5M | $238.0M | $250.1M | $293.3M | $358.1M | $363.8M |
| Gross profit | $107.0M | $131.9M | $143.3M | $199.7M | $248.9M | $351.1M | $373.9M | $356.1M |
| Gross margin | 36.3% | 40.9% | 41.0% | 45.6% | 49.9% | 54.5% | 51.1% | 49.5% |
| R&D | $57.6M | $68.9M | $67.2M | $60.9M | $74.8M | $73.7M | $73.9M | $85.8M |
| Operating income | −$8.6M | −$39.0K | $11.0M | $69.9M | $107.5M | $197.0M | $205.4M | $140.4M |
| EBITDA | $6.8M | $81.5M | $30.2M | $111.6M | $146.2M | $240.3M | $277.3M | $212.3M |
| Net income | −$5.7M | $48.9M | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | $98.1M |
| Net margin | -1.9% | 15.2% | 0.4% | 14.2% | 18.3% | 21.3% | 21.8% | 13.6% |
| EPS (diluted) | -0.12 | 0.98 | 0.03 | 1.25 | 1.74 | 2.60 | 3.06 | 2.03 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $747M | $2.68 | $2.47–$2.82 | 3 |
| 2027 | $788M | $3.14 | $3.01–$3.23 | 3 |
| 2028 | $809M | $3.40 | $3.28–$3.51 | 1 |
| 2029 | $836M | $2.60 | $2.51–$2.68 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$128.22
Price
$20.71
Implied upside
+519%
Peer comparison
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
www.amphastar.com- Employees
- 1,976
- IPO / List date
- Jun 25, 2014
- HQ
- RANCHO CUCAMONGA, CA
Held by traders on TradeandTell
No one on the platform currently holds AMPH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 553,900 | $10.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AMPH yet.
